| Bioactivity | Blebbistatin is a selective non-muscle myosin II (NMII) inhibitor, promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, and better preserves cell junctional integrity and barrier function. Blebbistatin blocks cell migration[1][2]. | |||||||||
| Target | Non-muscle myosin II (NMII) | |||||||||
| Invitro | The therapeutic potential of targeting NMII to enhance CEC migration is investigated using bovine corneal endothelial cells (BCECs). Blebbistatin, a direct myosin motor inhibitor, promotes migration and directional persistence in CECs through decreasing actin retrograde flow and increasing lamellipodial protrusion persistence to accelerate wound healing in vitro[1]. | |||||||||
| In Vivo | Blebbistatin (0.05 mL, 20 μM; intracameral injection; daily; for 6 days; New Zealand white rabbits) treatment promotes wound healing in rabbit corneal endothelial scraping model[1]. Animal Model: | |||||||||
| Name | Blebbistatin | |||||||||
| CAS | 674289-55-5 | |||||||||
| Formula | C18H16N2O2 | |||||||||
| Molar Mass | 292.33 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Ho WT, et al. Targeting non-muscle myosin II promotes corneal endothelial migration through regulating lamellipodial dynamics. J Mol Med (Berl). 2019 Sep;97(9):1345-1357. [2]. Liang Ma, et al. Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration. Cell Res. 2015 Jan;25(1):24-38. |
Blebbistatin
CAS: 674289-55-5 F: C18H16N2O2 W: 292.33
Blebbistatin is a selective non-muscle myosin II (NMII) inhibitor, promotes directional migration of corneal endothelial
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.